PCM
APLS

Prelude Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Prelude Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$6K – 1415
2019
Q4 		$6K Buy
+200
New +$5.54K ﹤0.01% 1753

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Prelude Capital Management's APLS Position: Q1 2026 in Review

Prelude Capital Management increased its Apellis Pharmaceuticals (APLS) stake by 189% in Q1 2026, buying an estimated $1.57M and bringing the position to 111,468 shares worth $4.48M. The position accounts for 0.34% of the portfolio, ranked #65.

Prelude Capital Management first reported a position in APLS in Q4 2018 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Prelude Capital Management held 111,468 shares of Apellis Pharmaceuticals worth $4.48M as of Q1 2026.
  • Prelude Capital Management bought 72,947 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.57M.
  • Apellis Pharmaceuticals made up 0.34% of Prelude Capital Management's portfolio in Q1 2026, its #65 holding.
  • Prelude Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.